Insmed Inc (INSM)vsVertex Pharmaceuticals Inc (VRTX)
INSM
Insmed Inc
$101.49
-1.58%
HEALTHCARE · Cap: $23.48B
VRTX
Vertex Pharmaceuticals Inc
$481.70
-0.34%
HEALTHCARE · Cap: $119.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 1391% more annual revenue ($12.22B vs $819.56M). VRTX leads profitability with a 35.5% profit margin vs -144.4%. INSM appears more attractively valued with a PEG of 1.09. VRTX earns a higher WallStSmart Score of 68/100 (B-).
INSM
Hold39
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-24.6%
Fair Value
$84.03
Current Price
$101.49
$17.46 premium
Margin of Safety
+49.1%
Fair Value
$941.26
Current Price
$481.70
$459.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 229.6% year-over-year
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Elevated debt levels
Trading at 31.1x book value
ROE of -167.9% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
The strongest argument for INSM centers on Revenue Growth. Revenue growth of 229.6% demonstrates continued momentum. PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : INSM
The primary concerns for INSM are EPS Growth, Debt/Equity, Price/Book.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
INSM profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
INSM carries more volatility with a beta of 0.78 — expect wider price swings.
INSM is growing revenue faster at 229.6% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 39/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?